Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 4/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 7/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.43 |
| ▸ | AR | P10275 | 3/20 | 0.43 |
| ▸ | TOP1 | P11387 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2323759 | 0.99 | PDE3B (0.47) | PDE3BPDE3AP2RY12PDE10ACYP1A2 | |
| SCHEMBL2323506 | 0.99 | PDE3B (0.47) | PDE3BPDE3AP2RY12PDE10ACYP1A2 | |
| SCHEMBL2326865 | 0.97 | PDE3B (0.51) | PDE3BPDE3AP2RY12PDE10ACYP1A2 | |
| SCHEMBL2323254 | 0.94 | PDE3B (0.45) | PDE3BPDE3AP2RY12PDE10ACYP1A2 | |
| SCHEMBL2324240 | 0.94 | SIRT2 (0.46) | PDE3BPDE3AP2RY12PDE10ACYP1A2 | |
| SCHEMBL2329630 | 0.94 | AR (0.46) | PDE3BPDE3AP2RY12PDE10ACYP1A2 | |
| SCHEMBL2326861 | 0.93 | PDE3B (0.44) | PDE3BPDE3AP2RY12PDE10ACYP1A2 | |
| SCHEMBL2325270 | 0.93 | AR (0.46) | PDE3BPDE3AP2RY12PDE10ACYP1A2 | |
| SCHEMBL2329243 | 0.93 | PDE3B (0.44) | PDE3BPDE3AP2RY12PDE10ACYP1A2 | |
| SCHEMBL2323414 | 0.93 | PDE3B (0.45) | PDE3BPDE3AP2RY12PDE10ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246808-B1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | BAYER SCHERING PHARMA AG (DE) | 2011-08-17 | — | — | EP | claimed |
| US-7345075-B2 | 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester; antiinflammatory agents; microglia activators; neurodegenerative diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-03-18 | — | — | US | claimed |
| US-20060211690-A1 | Microglia inhibitors for interrupting interleukin 12 and IFNgamma-mediated immune reactions | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-21 | — | — | US | claimed |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | claimed |
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | SCHERING AG | 2002-01-17 | — | — | US | claimed |
| EP-1246808-B1 | 1,2-DIARYL BENZIMIDAZOLES FOR TREATING ILLNESSES ASSOCIATED WITH A MICROGLIA ACTIVATION | BAYER SCHERING PHARMA AG (DE) | 2011-08-17 | — | — | EP | disclosed |
| US-7345075-B2 | 6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanoic acid isopropyl ester; antiinflammatory agents; microglia activators; neurodegenerative diseases | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-03-18 | — | — | US | disclosed |
| US-7329679-B2 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-02-12 | — | — | US | disclosed |
| US-7115645-B2 | 1,2 diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-14 | — | — | US | disclosed |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-04 | — | — | US | disclosed |
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | SCHERING AG | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211690-A1 | Microglia inhibitors for interrupting interleukin 12 and IFNgamma-mediated immune reactions | IFNG, GMFG, MMP12 | PDE3B 734/4885PDE3A 1196/4885P2RY12 45/4885 |
| US-20020006948-A1 | 1,2 diarylbenzimdazoles and their pharmaceutical use | CYP2E1, CYP1B1, CYP1A1 | PDE3B 362/4885PDE3A 483/4885P2RY12 565/4885 |
| US-20060094770-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | PDE3B 319/4885PDE3A 415/4885P2RY12 232/4885 |
| US-20060205803-A1 | 1,2 Diarylbenzimidazoles and their pharmaceutical use | ATP6V1B2, IL1B, GMFG | PDE3B 319/4885PDE3A 415/4885P2RY12 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.